Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics
Key Highlights of the Report
- Splash Beverage Group (NYSE American: SBEV) has announced a major expansion of its pharmaceutical platform.
- The company has broadened its exclusive global license for CannEpil® to include veterinary therapeutic applications, establishing a second FDA-regulated pharmaceutical development program alongside its existing human pharmaceutical program.
- Splash now holds exclusive worldwide rights to develop, manufacture, commercialize, market, and distribute CannEpil for veterinary diseases and conditions.
- CannEpil® is a proprietary pharmaceutical-grade cannabinoid formulation (CBD and THC) manufactured under European Union Good Manufacturing Practice (EU-GMP) standards.
- Originally developed for drug-resistant epilepsy, CannEpil has previously been supplied through physician-directed access programs in international markets and carries an FDA Investigational New Drug (IND) application number for its human program.
- Splash intends to initially evaluate CannEpil for companion-animal oncology and chronic pain management, with a focus on canine indications.
- The company plans to pursue U.S. regulatory approval via the FDA Center for Veterinary Medicine’s Investigational New Animal Drug (INAD) and Conditional Approval pathways.
Market Opportunity & Price-Sensitive Information
- Splash’s entry into veterinary therapeutics positions CannEpil within two rapidly growing sectors: veterinary pain management (valued at \$2.6 billion in 2024 and projected to reach \$3.8 billion by 2030) and veterinary oncology (estimated between \$900 million and \$1.7 billion globally).
- The patient population is substantial: one in four dogs develop cancer during their lifetime and half of dogs over age ten will develop cancer. Estimates suggest six million dogs are diagnosed with cancer each year in the U.S.
- Splash will pay Argent BioPharma Limited a 10% royalty on net revenues generated from veterinary applications of CannEpil, which could impact future earnings and shareholder value.
- A strategic joint venture is being finalized with an experienced cannabinoid pharmaceutical company to lead the veterinary development program, featuring executives with a proven track record of regulatory approval and commercialization in cannabinoid medicines. Details of this partnership are expected soon and could be material for investors.
Strategic Implications & Shareholder Impact
- This expansion materially broadens the commercial value of the CannEpil platform, giving Splash access to significant companion-animal oncology and pain-management markets.
- The company is executing a diversified cannabinoid health sciences strategy by commercializing international pharmaceutical assets, advancing FDA-regulated veterinary and human therapeutics, and developing cannabinoid consumer wellness and beverage brands.
- Regulatory engagement with the FDA and other authorities will determine development timelines, target indications, and clinical requirements. Investors should be aware that there is no assurance of regulatory approval or commercialization success at this stage.
- Potential risks include inability to obtain or maintain intellectual property rights, failure to negotiate or execute the joint venture, capital requirements, compliance with regulations, and evolving industry standards, all of which could impact share value.
About CannEpil®
CannEpil® is a proprietary pharmaceutical-grade cannabinoid formulation consisting of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates in an oral liquid solution, manufactured under EU-GMP standards. Originally supplied through physician-directed access programs, it is now being advanced for additional pharmaceutical indications, including veterinary use.
About Splash Beverage Group, Inc.
Splash Beverage Group, Inc. (NYSE American: SBEV) is a publicly traded company headquartered in Fort Lauderdale, Florida. The company is pursuing a strategic transformation toward becoming a cannabinoid health, wellness, and biopharmaceutical platform through disciplined capital allocation, strategic investments, acquisitions, and other platform-building initiatives.
Investor Contact Information
- Email: [email protected]
- Media Contact: Angela Gorman, AMWPR ([email protected], 917-348-0083)
Forward-Looking Statements & Disclaimer
This article contains forward-looking statements, including plans to develop and commercialize CannEpil for veterinary applications, anticipated regulatory pathways, market projections, completion of a joint venture, and other strategic initiatives. These statements are subject to risks and uncertainties, including regulatory approval, intellectual property issues, partnership execution, capital requirements, and evolving industry regulations. There is no guarantee that CannEpil will receive regulatory approval or achieve commercial success for any indication.
Disclaimer: The information provided herein is for informational purposes only and does not constitute investment advice. Investors are cautioned to conduct their own due diligence and consult with financial advisors prior to making any investment decisions. Splash Beverage Group undertakes no obligation to update forward-looking statements except as required by law.
